New York, USA - December 29, 2025 - Alfa Cytology has expanded its capabilities in therapeutic antibody development with the proBsAb™ platform, a specialized framework for bispecific and multispecific antibody engineering in cancer-related research. As combination therapy becomes more common in cancer therapy, antibody engineering, bispecific, and multispecific antibody formats are increasingly explored to investigate tumor heterogeneity and immune escape mechanisms. This trend reflects the need for platforms that can meet the structural and functional demands of advanced antibody formats.
Researchers and biotechnology companies have long faced comparable hurdles in developing bispecific and multispecific antibodies, particularly in achieving correct molecular assembly, maintaining stability of expression, and establishing reliable functional assays. The proBsAb™ platform is structured to better solve these challenges by covering key stages of bispecific and multispecific antibody engineering within an optimized development process. Major services include antigen preparation, antibody discovery by multiple approaches, format selection, molecular engineering, expression optimization, purification, and functional evaluation, resulting in a complete pipeline for antibody research and preclinical studies.
The proBsAb™ platform accommodates a broad range of next-generation bispecific and multispecific antibody formats, including IgG-like bispecific antibodies, T-cell engagers, dual-variable domain antibodies, trispecific constructs, and single-domain antibody structures. This array of services helps researchers adapt antibody structures to specific biological questions, such as facilitating the redirection of immune cells to a tumor target or simultaneously activating multiple signaling pathways involved in cancer biology.
Beyond bispecific and multispecific antibodies, the proBsAb™ platform also covers antibody fragments and antibody-based T-cell-engaging structures that are commonly incorporated into complex multispecific designs. This capability enables the development of next-generation bispecific antibody solutions, ensuring structural integrity and functional verification. Additional engineering modifications, such as affinity tuning, humanization, and stability improvement, can be performed to meet the requirements of subsequent evaluation and preclinical studies. To guarantee consistent results across studies, antibodies developed on the proBsAb™ platform are confirmed structurally and tested for in vitro activity to verify their function.
"Even small changes in advanced antibody formats can lead to measurable differences," said a representative from Alfa Cytology. "The proBsAb™ platform brings together construction strategies, expression systems, and evaluation methods in a way that allows these variables to be examined systematically during preclinical cancer research."
About Alfa Cytology
Alfa Cytology specializes in cancer biology, immunology, and therapeutic antibody development, with a strong focus on bispecific and multispecific antibody engineering through platforms such as proBsAb™. From antigen preparation and antibody generation to functional and stability testing, Alfa Cytology covers the early and preclinical stages of research. In cancer research in particular, the company continues to deepen partnerships with academic institutions, biotechnology companies, and research organizations to provide long-term support for preclinical research.
Media Contact
Company Name: Alfa Cytology
Contact Person: Toya Davis
Email: Send Email
Country: United States
Website: https://www.alfacytology.com
